Panbela to Hold Q1 2024 Earnings Call on May 15, 2024

Panbela Therapeutics, Inc., located in Minneapolis, announced it will conduct a conference call on May 15, 2024, at 4:30 PM Eastern Time to review the results of its first quarter ending March 31, 2024. Panbela is a clinical-stage company focusing on developing innovative therapeutics for patients with critical unmet medical needs.

The company's pipeline includes several promising assets under clinical trials, primarily targeting conditions such as familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, and ovarian cancer. Panbela's development programs span from pre-clinical stages to registration studies, ensuring a consistent progression of anticipated clinical milestones.

One of Panbela's notable assets is Ivospemin (SBP-101), a proprietary polyamine analogue aimed at inducing polyamine metabolic inhibition (PMI). This is achieved by leveraging the compound's high affinity for pancreatic ductal adenocarcinoma and other tumors. In clinical trials involving patients with metastatic pancreatic cancer, Ivospemin has demonstrated promising results, including a median overall survival (OS) of 14.6 months and an objective response rate (ORR) of 48%. These outcomes surpass the typical results seen with standard treatments like gemcitabine combined with nab-paclitaxel, indicating a potential complementary effect with the current FDA-approved chemotherapy regimen. Importantly, Ivospemin has not shown increased bone marrow suppression or peripheral neuropathy, common adverse effects of chemotherapy. Serious visual side effects have been assessed, and future studies will exclude patients with a history of retinopathy or those at risk of retinal detachment. The safety data and PMI profile observed in previous trials support the continued evaluation of Ivospemin in the ongoing ASPIRE trial.

Flynpovi ™, another significant asset, is a combination of CPP-1X (eflornithine) and sulindac. This combination works through a dual mechanism: inhibiting polyamine synthesis and enhancing polyamine export and catabolism. In a Phase III clinical trial with patients having sporadic large bowel polyps, Flynpovi successfully prevented over 90% of subsequent pre-cancerous sporadic adenomas compared to a placebo. In a recent Phase III trial focused on FAP patients, particularly those with lower gastrointestinal (GI) anatomy, Flynpovi showed statistically significant benefits in delaying surgical events in the lower GI tract for up to four years compared to both single agents. The safety profile of Flynpovi aligns closely with that of its individual components, supporting its continued evaluation for FAP.

CPP-1X (eflornithine) is being developed as a single-agent tablet or high-dose powder sachet for multiple indications, including gastric cancer prevention, neuroblastoma treatment, and recent onset Type 1 diabetes. Preclinical studies and Phase I or II investigator-initiated trials suggest that CPP-1X treatment is potentially well-tolerated and shows promising activity.

Panbela Therapeutics, Inc. is committed to developing breakthrough therapeutics for patients with urgent unmet medical needs. The company’s leading assets, Ivospemin (SBP-101) and Flynpovi, are central to its mission. Panbela’s common stock is quoted on the OTCQB under the symbol “PBLA.” Additional information about Panbela can be found on their official website.